PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $216 | -35.9% | 12,954 | +6.1% | 0.00% | -50.0% |
| Q2 2023 | $337 | +29.1% | 12,214 | +7.5% | 0.00% | 0.0% |
| Q1 2023 | $261 | +115.7% | 11,367 | +2.1% | 0.00% | +100.0% |
| Q4 2022 | $121 | -99.9% | 11,128 | -6.8% | 0.00% | 0.0% |
| Q3 2022 | $101,000 | -52.1% | 11,946 | +33.8% | 0.00% | 0.0% |
| Q1 2022 | $211,000 | -27.0% | 8,927 | +5.5% | 0.00% | 0.0% |
| Q4 2021 | $289,000 | – | 8,464 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
| Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
| Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
| Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
| Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
| RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
| Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
| Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
| Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
| BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |